Lilly(US:LLY) Zheng Quan Ri Bao·2025-03-30 08:45Core Viewpoint - Eli Lilly China announced the launch of its innovative drug, Donanemab (记能达®), for early-stage Alzheimer's disease treatment in China, aiming to significantly slow disease progression and improve patients' quality of life [2]. Group 1: Product Launch and Approval - Donanemab received approval from the National Medical Products Administration (NMPA) on December 17, 2024, for treating adults with mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease [2]. - The drug is administered once a month and is the only therapy with evidence supporting the possibility of discontinuation, targeting amyloid pathology [2]. Group 2: Market Context and Implications - The launch of Donanemab comes at a time when the aging population in China is increasing, prompting the government to enhance Alzheimer's disease prevention and control capabilities [2]. - Eli Lilly aims to provide a new treatment option that addresses the disease's underlying mechanisms, potentially alleviating the social burden associated with aging [2]. Group 3: Company Commitment and Future Directions - Eli Lilly expresses a commitment to collaborate with stakeholders to contribute positively to Alzheimer's disease prevention and the establishment of a dementia-friendly society in China [2]. - The company advocates for innovative mechanisms to promote early implementation of policies, enhance disease awareness, and build a consensus on the preventability and treatability of dementia in older adults [2].